Clear Search

Showing 1 result for “Cagnoli PC” published 2024.

September 2024

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study

Ann Rheum Dis 2024;0:1–11 DOI 10.1136/ard-2024-225686.

Aranow et al. evaluated the efficacy and safety of combining subcutaneous belimumab with one cycle of rituximab in SLE. Sequential therapy did not show a statistically significant improvement in disease control over belimumab monotherapy, but did achieve nominally better reductions in disease activity markers.

more…